Press release
Epithelial Ovarian Cancer Market Research Reveals Path To $5.03 Billion By 2030
Epithelial Ovarian Cancer Market
Projected Growth Trajectory of the Epithelial Ovarian Cancer Market
The market for epithelial ovarian cancer treatments is anticipated to expand rapidly, reaching a value of $5.03 billion by 2030. This growth reflects a compound annual growth rate (CAGR) of 15.7%. Key contributors to this upward trend include the increasing use of precision oncology, biomarker-driven diagnostics, expansion in immunotherapy options, greater awareness around early screening, and improvements in patient survival rates. Noteworthy market trends expected during this timeframe feature the rising acceptance of targeted therapies, wider implementation of combination treatment regimens, advancements in early diagnostic tools, broader immunotherapy applications, and a stronger focus on personalized oncology care.
The epithelial ovarian cancer market size has grown rapidly in recent years. It will grow from $2.41 billion in 2025 to $2.8 billion in 2026 at a compound annual growth rate (CAGR) of 16.2%. The growth in the historic period can be attributed to late-stage diagnosis prevalence, chemotherapy usage, aging female population, oncology infrastructure growth, clinical trial expansion.
Download a free sample of the epithelial ovarian cancer market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20778&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Key Players Shaping the Epithelial Ovarian Cancer Market
Several leading pharmaceutical and biotech companies are actively involved in this market, including Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Clovis Oncology Inc., and Fujirebio Diagnostics Inc.
A significant development occurred in February 2024 when AbbVie Inc., a US-based biopharmaceutical firm, acquired ImmunoGen for $10.1 billion. This strategic acquisition strengthens AbbVie's oncology portfolio by incorporating ELAHERE, an antibody-drug conjugate designed specifically for treating platinum-resistant ovarian cancer. The move reduces dependence on AbbVie's older medications and enhances its position within the burgeoning antibody-drug conjugate (ADC) sector. ImmunoGen specializes in developing therapies targeting epithelial ovarian cancer.
Emerging Treatment Trends in the Epithelial Ovarian Cancer Market
Major companies are increasingly focusing on innovative therapies such as FRa-directed antibody-drug conjugates (ADCs), which are designed to target folate receptor-alpha, a protein frequently ere*xpressed on ovarian cancer cells. These ADCs deliver potent cytotoxic drugs directly to cancer cells, minimizing damage to healthy tissue.
For instance, in November 2024, AbbVie received approval from the European Commission for ELAHERE (mirvetuximab soravtansine), a targeted therapy intended for adult patients with folate receptor-alpha positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. This drug offers a promising new option for individuals who have undergone up to three prior systemic treatments. ELAHERE's companion diagnostic helps identify patients most likely to benefit, improving survival chances and overall quality of life.
View the full epithelial ovarian cancer market report:
https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Main Segments of the Global Epithelial Ovarian Cancer Market
The epithelial ovarian cancer market report segments the industry into several critical categories:
1) By Type of Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Surgery
2) By Drug Class: Platinum-Based Chemotherapy Drugs, Poly (ADP-ribose) Polymerase (PARP) Inhibitors, Bevacizumab, Chemotherapeutic Agents
3) By Stage of Cancer: Early Stage, Advanced Stage
4) By Diagnosis Method: Imaging, Biopsy, Blood Tests
5) By End User: Hospitals, Clinics, Diagnostic Laboratories
Further subcategories include:
- Chemotherapy: Platinum-Based, Non-Platinum, Combination Chemotherapy
- Targeted Therapy: Monoclonal Antibodies, PARP Inhibitors, Angiogenesis Inhibitors
- Immunotherapy: Checkpoint Inhibitors, Cancer Vaccines, Adoptive T-Cell Therapy
- Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Progestins
- Surgery: Debulking Surgery, Oophorectomy, Hysterectomy
These classifications provide a comprehensive framework for understanding the market's scope and diversity of treatment options available for epithelial ovarian cancer.
New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epithelial Ovarian Cancer Market Research Reveals Path To $5.03 Billion By 2030 here
News-ID: 4606688 • Views: …
More Releases from The Business Research Company
External Fixation System Market Trends Support A 8.3% CAGR Outlook Through The F …
The external fixation system market is on the verge of significant expansion, driven by technological progress and shifting healthcare dynamics. This sector plays a crucial role in orthopedic treatments, especially in trauma care, and is expected to evolve rapidly as new innovations and demographic factors come into play. Let's explore the current market size, the key players involved, emerging trends, and segmentation insights that define the future landscape of this…
Exosome Technologies Market Report Examines Industry Trends, Growth Drivers And …
The exosome technologies market is on the brink of remarkable expansion, driven by advancements in diagnostics, personalized medicine, and therapeutic developments. As interest and investment in this field accelerate, the industry is poised to deliver transformative healthcare solutions over the coming years. Let's delve into the current market size, key players, emerging trends, and segmentation to better understand this dynamic sector.
Forecasted Market Growth of the Exosome Technologies Market
The…
Excimer Laser Market Report Examines Leading Companies And Growth Opportunities
The excimer laser market is on track for significant expansion as new technologies and applications continue to emerge. With advancements in medical treatments and industrial processes, this sector is set to experience robust growth through 2030. Let's explore the market's size, key drivers, major players, trends, and detailed segment analysis to understand the opportunities ahead.
Projected Growth and Market Size of the Excimer Laser Sector
The excimer laser market is…
Esoteric Testing Market Outlook Highlights Strategic Opportunities Across The In …
A closer look at the esoteric testing market reveals a sector on the brink of substantial expansion. With advances in medical technology and a rising demand for specialized diagnostics, this market is set to transform healthcare by enabling more precise and personalized patient care. Below, we explore the market's size, major players, prevailing trends, and key segments shaping its future.
Projected Growth and Market Value of the Esoteric Testing Market …
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
